CCL21 is associated with fatal outcomes in chronic heart failure: Data from CORONA and GISSI-HF trials

European Journal of Heart Failure

Volumn 15, Issue 7, 2013, Pages 747-755

  Ueland, Thor ^a,b   Nymo, Ståle H ^a   Latini, Roberto ^c   McMurray, John J V ^d   Kjekshus, John ^a   Yndestad, Arne ^a   Fucili, Alessandro ^e   Grosu, Aurelia ^f   Masson, Serge ^c   Maggioni, Aldo P ^g   Gullestad, Lars ^a   Aukrust, Pål ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^f OSPEDALI RIUNITI   (Italy)

^g ANMCO RESEARCH CENTER   (Italy)

Author keywords

CCL21; Heart failure; Inflammation; Survival analysis

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; ROSUVASTATIN; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; FATALITY; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; RISK FACTOR;

EID: 84879475862     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hft031     Document Type: Article

References (24)

1. Bozkurt B, Mann DL, Deswal A. Biomarkers of inflammation in heart failure. Heart Fail Rev 2010;15:331-341.
2. Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P. Role of inflammation in the progression of heart failure. Curr Cardiol Rep 2007;9:236-241. (Pubitemid 46784419)
3. Wrigley BJ, Lip GY, Shantsila E. The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail 2011;13:1161-1171.
4. Forster R, Valos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 2008;8:362-371. (Pubitemid 351595218)
5. Menning A, Hopken UE, Siegmund K, Lipp M, Hamann A, Huehn J. Distinctive role of CCR7 in migration and functional activity of naive-and effector/memory-like Treg subsets. Eur J Immunol 2007;37:1575-1583. (Pubitemid 46939492)
6. Schneider MA, Meingassner JG, Lipp M, Moore HD, Rot A. CCR7 is required fo the in vivo function of CD4+ CD25+ regulatory T cells. J Exp Med 2007;204: 735-745. (Pubitemid 46631604)
7. Damas JK, Smith C, Oie E, Fevang B, Halvorsen B, Waehre T, Boullier A, Breland U, Yndestad A, Ovchinnikova O, Robertson AK, Sandberg WJ, Kjekshus J, Tasken K, Froland SS, Gullestad L, Hansson GK, Quehenberger O, Aukrust P. Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization. Arterioscler Thromb Vasc Biol 2007;27:614-620.
8. Pierce EM, Carpenter K, Jakubzick C, Kunkel SL, Evanoff H, Flaherty KR, Martinez FJ, Toews GB, Hogaboam CM. Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 21. Eur Respir J 2007;29: 1082-1093. (Pubitemid 46895366)
9. Yndestad A, Finsen AV, Ueland T, Husberg C, Dahl CP, Øie E, Vinge LE, Sjaastad I, Sandanger Ø, Ranheim T, Dickstein K, Kjekshus J, Damas JK, Fiane AE, Hilfiker-Kleiner D, Lipp M, Gullestad L, Christensen G, Aukrust P. The homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure. PlosOne 2012;7:e33038.
10. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebocontrolled trial. Lancet 2008;372:1231-1239.
11. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-2261. (Pubitemid 350190755)
12. Latini R, Gullestad L, Masson S, Nymo SH, Ueland T, Cuccovillo I, Vardal M, Bottazzi B, Mantovani A, Lucci D, Masuda N, Sudo Y, Wikstrand J, Tognoni G, Aukrust P, Tavazzi L. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail 2012;14:992-999.
13. Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson A, McMurray JV, Waagstein F, Wedel H, Wessman P, Wikstrand J. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005;7: 1059-1069. (Pubitemid 41443603)
14. Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, Nicolosi GL, Porcu M. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004;6:635-641. (Pubitemid 39070519)
15. Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson A, McMurray JV, Waagstein F, Wedel H, Wessman P, Wikstrand J. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005;7: 1059-1069. (Pubitemid 41443603)
16. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
17. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323: 236-241. (Pubitemid 20225044)
18. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Oie E, Otterdal K, Gullestad L, Damas JK. Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol 2008;28:1909-1919.
19. Hohensinner PJ, Rychli K, Zorn G, Hulsmann M, Berger R, Mortl D, Richter B, Huber K, Wojta J, Pacher R, Niessner A. Macrophage-modulating cytokines predict adverse outcome in heart failure. Thromb Haemost 2010;103:435-441.
20. Nykanen AI, Sandelin H, Krebs R, Keranen MA, Tuuminen R, Karpanen T, Wu Y, Pytowski B, Koskinen PK, Yla-Herttuala S, Alitalo K, Lemstrom KB. Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts. Circulation 2010;121:1413-1422.
21. Lanati S, Dunn DB, Roussigne M, Emmett MS, Carriere V, Jullien D, Budge J, Fryer J, Erard M, Cailler F, Girard JP, Bates DO. Chemotrap-1: an engineered soluble receptor that blocks chemokine-induced migration of metastatic cancer cells in vivo. Cancer Res 2010;70:8138-8148.
22. Cleland JG, McMurray JJ, Kjekshus J, Cornel JH, Dunselman P, Fonseca C, Hjalmarson A, Korewicki J, Lindberg M, Ranjith N, van Veldhuisen DJ, Waagstein F,Wedel H, Wikstrand J. Plasma concentration of amino-terminal probrain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2009;54:1850-1859.
23. Masson S, Latini R, Carbonieri E, Moretti L, Rossi MG, Ciricugno S, Milani V, Marchioli R, Struck J, Bergmann A, Maggioni AP, Tognoni G, Tavazzi L. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 2010;12:338-347.
24. Wedel H, McMurray JJ, Lindberg M, Wikstrand J, Cleland JG, Cornel JH, Dunselman P, Hjalmarson A, Kjekshus J, Komajda M, Kuusi T, Vanhaecke J, Waagstein F. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 2009;11:281-291.